Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma
Authors:
- Jill M. KolesarJKJill M. Kolesar
- 1 January 2009
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 31, 2290-2311
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trialBritish Journal of Haematology, 2008
- Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitroJournal of Cancer Research and Clinical Oncology, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Bendamustine hydrochloride in patients with refractory soft tissue sarcomaCancer, 2007
- A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumoursBritish Journal of Cancer, 2007
- Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)Journal of Cancer Research and Clinical Oncology, 2006
- Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapyJournal of Cancer Research and Clinical Oncology, 2005
- Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)Journal of Cancer Research and Clinical Oncology, 2005
- High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomasJournal of Cancer Research and Clinical Oncology, 2002